Profiling immune cells in patients with HBV-related acute-on-chronic liver failure
Single-cell Landscape of Immunological Responses in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure
This study looks at the immune cells in the blood of patients with HBV-related liver failure to see how they might be affecting the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 21 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06865859 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the immune cells in the peripheral blood of patients suffering from HBV-related acute-on-chronic liver failure using single-cell RNA sequencing. By examining the immune cell characteristics, the study seeks to uncover the immunopathological mechanisms underlying this complex condition, which is marked by acute liver function deterioration and high mortality rates. The research combines advanced single-cell transcriptomics with molecular biology techniques to provide insights into the pathogenesis of HBV-related chronic liver disease and acute-on-chronic liver failure.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with HBV-related acute-on-chronic liver failure who meet specific clinical criteria.
Not a fit: Patients with other types of hepatitis infections, primary liver cancer, or severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of the immune mechanisms involved in HBV-related acute-on-chronic liver failure, potentially guiding the development of targeted therapies.
How similar studies have performed: While this approach using single-cell RNA sequencing is innovative, similar studies have shown promise in understanding immune responses in other liver diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Acute liver failure is a well-defned medical emergency which is defned as a severe liver injury, leading to coagulation abnormality usually with an INR ≥ 1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing liver disease and with an illness of up to 4 weeks duration Exclusion Criteria: * Associated with other types of hepatitis virus infection or HIV infection, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury; ② Suffering from primary liver cancer or severe heart, digestive, lung, kidney, neurological and psychiatric diseases; ③ Patients with incomplete data and patients unable to participate in the experiment.
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Yu-Chen Fan
- Email: fanyuchen@sdu.edu.cn
- Phone: 0086+053182169593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.